Get the Stockscreener App
1.13
5.04%
-0.06
After Hours:
1.14
0.01
+0.88%
Lucid Diagnostics Inc stock is traded at $1.13, with a volume of 684.98K.
It is down -5.04% in the last 24 hours and down -31.52% over the past month.
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.
See More
Previous Close:
$1.19
Open:
$1.19
24h Volume:
684.98K
Relative Volume:
0.66
Market Cap:
$135.09M
Revenue:
$4.35M
Net Income/Loss:
$-45.53M
P/E Ratio:
-1.0463
EPS:
-1.08
Net Cash Flow:
$-44.79M
1W Performance:
-12.06%
1M Performance:
-31.52%
6M Performance:
+8.65%
1Y Performance:
+21.54%
1-Day Range:
$1.12
$1.2076
1-Week Range:
$1.12
$1.30
52-Week Range:
$0.681
$1.80
Lucid Diagnostics Inc Stock (LUCD) Company Profile
Name
Lucid Diagnostics Inc
Sector
Industry
Phone
212 949 4319
Address
360 MADISON AVENUE, NEW YORK
Compare LUCD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LUCD
Lucid Diagnostics Inc
|
1.13 | 135.09M | 4.35M | -45.53M | -44.79M | -1.08 |
|
ABT
Abbott Laboratories
|
133.24 | 231.09B | 42.34B | 13.50B | 6.66B | 7.71 |
|
BSX
Boston Scientific Corp
|
102.86 | 155.24B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
380.92 | 144.54B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
83.48 | 108.82B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
73.68 | 44.31B | 5.54B | 4.18B | 623.10M | 7.00 |
Lucid Diagnostics Inc Stock (LUCD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-27-21 | Initiated | Ascendiant Capital Markets | Buy |
| Nov-08-21 | Initiated | BTIG Research | Buy |
| Nov-08-21 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-08-21 | Initiated | Needham | Buy |
Lucid Diagnostics Inc Stock (LUCD) Latest News
Financial Analysis: Lucid Diagnostics Inc (LUCD)’s Ratios Unveil Key Insights - DWinneX
Will Lucid Diagnostics Inc. (LUCD) Report Negative Earnings Next Week? What You Should Know - Yahoo Finance
Lucid Diagnostics Inc. (NASDAQ:LUCD) Shares Bought by Geode Capital Management LLC - Defense World
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on May 14, 2025 - Kilgore News Herald
LPL Financial LLC Raises Stock Holdings in Lucid Diagnostics Inc. (NASDAQ:LUCD) - Defense World
PAVmed Sets Key Q1 2025 Earnings Call: MedTech Growth Strategy and Financial Results Coming May 15 - Stock Titan
Lucid reports encouraging results from EsoGuard study - MSN
Lucid Diagnostics (LUCD) Showcases Promising Data for EsoGuard T - GuruFocus
A look into Lucid Diagnostics Inc (LUCD)’s deeper side - Sete News
NCI-Sponsored Study Shows Positive Data for Lucid Diagnostics' EsoGuard® Esophageal DNA Test in Patients Without Symptomatic GERD - BioSpace
PAVmed, Lucid post encouraging results from EsoGuard study (LUCD:NASDAQ) - Seeking Alpha
Lucid Reports Positive Data For EsoGuard Esophageal DNA Test In Patients Without Symptomatic GERD - Nasdaq
Lucid DiagnosticsNarrowing Losses, Expanding Opportunities In Esophageal Cancer Care - RTTNews
Did Lucid Diagnostics Inc (LUCD) perform well in the last session? - uspostnews.com
Ascendiant Capital Markets Forecasts Strong Price Appreciation for Lucid Diagnostics (NASDAQ:LUCD) Stock - The AM Reporter
Lucid Diagnostics (NASDAQ:LUCD) Price Target Raised to $7.50 at Ascendiant Capital Markets - Defense World
Stock Performance Spotlight: Lucid Diagnostics Inc (LUCD) Ends the Day at 1.21, Up by 11.01 - DWinneX
Lucid Diagnostics (LUCD) Sees Price Target Increase Amid Growth Potential | LUCD Stock News - GuruFocus
Lucid Diagnostics Announces Record Quarterly EsoGuard® Test Volume - ADVFN
PAVmed Provides Business Update and Second Quarter 2024 Financial Results - ADVFN
Lucid Diagnostics finalizes public offering of common stock - Medical Buyer
Lucid Diagnostics’ (LUCD) Buy Rating Reiterated at Needham & Company LLC - Defense World
Lucid Diagnostics Announces Pricing of Public Offering of Common Stock - The Bradford Era
Lucid Diagnostics Closes $16.1 Million Public Offering - MSN
Lucid Diagnostics completes $16.1 million stock offering By Investing.com - Investing.com South Africa
Lucid Diagnostics Raises $16.1 Mln Through Public Offering To Support Corporate Growth - Nasdaq
Lucid Diagnostics stock falls after pricing capital raise of $15M via stock offering - MSN
Lucid Diagnostics Inc (LUCD) With A Potential Upside Of More Than -100.0% - stocksregister.com
Lucid Diagnostics: DNA Testing To Get Medicare Coverage, Driving Volumes, Says Bullish Analyst - Benzinga
Lucid Diagnostics Announces Closing of Public Offering of Common Stock - GuruFocus
Lucid Diagnostics completes $16.1 million stock offering - Investing.com Australia
Lucid Diagnostics Announces Closing Of Public Offering Of Common Stock - marketscreener.com
Indo-Asian News Service - Indo-Asian News Service (IANS)
Lucid Diagnostics Shares Fall After Pricing Stock Offering - marketscreener.com
Lucid Diagnostics Announces Public Stock Offering - TipRanks
Lucid Diagnostics Stock Sinks After-Hours On Equity Raise, But Retail Dives In Anyway - MSN
Lucid Diagnostics Announces Proposed Public Offering of Common Stock - The Malaysian Reserve
Lucid Diagnostics announces proposed public offering of common stock - MSN
Lucid Diagnostics Announces Pricing Of Public Offering Of Common Stock - MarketScreener
Lucid Diagnostics plans stock offering to boost capital By Investing.com - Investing.com South Africa
Lucid Diagnostics Announces Proposed Public Offering of Common S - GuruFocus
SEC Form 424B5 filed by Lucid Diagnostics Inc. - Quantisnow
Lucid Diagnostics plans stock offering to boost capital - Investing.com Australia
Lucid Diagnostics Announces Proposed Public Offering Of Common Stock - MarketScreener
Lucid Diagnostics Inc Stock (LUCD) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.11%
0.79%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):